Aspire Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 01-11-2024
- Paid Up Capital ₹ 4.72 Cr
as on 01-11-2024
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 20.00 Cr
as on 01-11-2024
About Aspire Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 4.72 Cr.
The company currently has active open charges totaling ₹20.00 Cr.
Ashish Chopda, Rishabh Chopda, Naveen Deshlahara, and One other member serve as directors at the Company.
- CIN/LLPIN
U24110CT2020PTC010922
- Company No.
010922
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Nov 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chhattisgarh
Industry
Company Details
- Location
Raipur, Chattisgarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aspire Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Chopda  | Director | 12-Nov-2020 | Current |
| Rishabh Chopda | Director | 12-Nov-2020 | Current |
| Naveen Deshlahara | Director | 01-Mar-2023 | Current |
| Usha Sharma | Director | 01-Mar-2023 | Current |
Financial Performance of Aspire Pharmaceuticals.
Aspire Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Aspire Pharmaceuticals?
In 2023, Aspire Pharmaceuticals had a public holding of 39.22%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Rishabh Laboratories Pvt LtdActive 30 years 11 monthsAshish Chopda and Rishabh Chopda are mutual person
- Regalis Life Sciences Private LimitedActive 8 years 5 months
Ashish Chopda and Rishabh Chopda are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 22 Dec 2023 | ₹20.00 Cr | Open |
How Many Employees Work at Aspire Pharmaceuticals?
Aspire Pharmaceuticals has a workforce of 0 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aspire Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aspire Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
